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ns has been noted the other authors of this series, it is a
aunting if not impossible task to include all of the relevant
dvances in congenital heart disease during the last 12
onths. I apologize in advance to those whose articles I may
ave missed. It is an exciting time in the field with an
ver-evolving improvement in management for a continuing
omplex group of patients.
URGERY AND FOLLOW-UP
ypoplastic left heart syndrome. The latest modification
f the Norwood stage I operation uses a right
entricular(RV)-pulmonary artery (PA) shunt instead of the
tandard aortic pulmonary shunt. Theoretically, the RV-PA
hunt will provide a more stable pulmonary circulation
long with higher aortic diastolic pressure to improve
oronary blood flow. Sano and et al. (1) reported 17 of 19
urvivors with two infants 2 kg. Pizarro et al. (2) com-
ared 36 consecutive patients undergoing stage I palliation
ith an RV-PA conduit with 20 patients who received a
tandard Blalock-Taussig shunt. They reported more favor-
ble postoperative hemodynamics with higher aortic dia-
tolic blood pressure, improved operative survival of 92%
ersus 70%, and less need for ventilatory manipulations to
alance Qp/Qs in the RV-PA conduit group. Many centers
ave switched to this modification for first-stage palliation
f this complex condition. Although a deleterious effect of
he ventriculotomy in the systemic ventricle at an early age
s a possible disadvantage of this approach, to date there is
o documented evidence for an increased incidence of this
omplication.
Ghanayem et al. (3) presented the results of a home
urveillance program for patients who were discharged after
rst-stage Norwood palliation. The program included a
aily log of weight and arterial oxygen saturation with
nstructions to contact their physician if their oxygen satu-
ation was 70%, acute weight loss of 30 g in 24 h, or
ailure to gain at least 20 g during a 3-day period. There was
mprovement in mortality, and others have attempted to
ractice such an intensive surveillance program. These
atients appear to be vulnerable to early morbidity and
ortality between stage I and the more stable stage II
uperior cava to pulmonary artery shunt, which is performed
t approximately three to six months of age. Interstage
ortality may be related to suboptimal coronary artery flow
From the Ann and Monroe Carell Family Professor of Pediatric Cardiology,
anderbilt Children’s Hospital, Nashville, Tennessee.pManuscript received March 25, 2004; accepted April 9, 2004.eserve and possibly shunt narrowing or thrombosis. The
ocumentation of the actual cause of interstage mortality is
till unclear in the majority of patients.
Against this background, Ashburn et al. (4) reported
utcomes for the Norwood operation in 710 neonates with
ritical aortic stenosis or aortic atresia as a part of the
ongenital Heart Surgeons Society prospective study.
verall survival was 72%, 60%, and 54% at one month, one
ear, and five years, respectively. Risk factors of early death
nclude lower birth weight, smaller ascending aorta, and
lder age at operation. Other variables affecting outcome
ppear to be a low number of operations at a center, shunt
riginating from the aorta, and longer circulatory arrest
ime. These studies from a large number of institutions in
he U.S. and Canada are valuable to spot trends and
ssociated risk factors for survival that may be eliminated
ith different management strategies.
ulmonary atresia with ventricular septal defect/tetralogy of
allot. Pulmonary atresia with ventricular septal defect
epresents another complex group of patients with extremely
ariable anatomy. Gupta et al. (5) reviewed a retrospective
eries of 104 patients treated with staged repair. The
0-year mortality was 16.5% but only 58 of 104 patients
chieved complete repair. The number of collateral vessels
ncorporated into the repair was a risk factor for death.
hese patients require meticulous management, and those
ith hypoplastic pulmonary arteries with multiple aortopul-
onary collateral arteries can be difficult to manage. Close
ollaboration between surgeons and interventionalists is
equired to achieve optimal results.
Duncan et al. (6) reported 46 consecutive patients with
taged repair of pulmonary atresia and major aortopulmo-
ary collateral arteries. The Melbourne shunt was used for
nitial palliation for patients with a central pulmonary artery.
wenty-seven patients subsequently underwent complete
epair with a median of three total operations, and 18
dditional patients are considered candidates for eventual
epair. The staged repair is used by most institutions.
thers have suggested that many of these patients may be
andidates for early one-stage repair. Direct comparison of
hese two strategies would be extremely valuable, although
he complex and variable anatomy makes it difficult to
atch patient groups.
Abella et al. (7) report on primary repair of pulmonary
tresia with ventricular septal defect and major aortopulmo-
ary collaterals with a radical new approach used in five
atients with a median age of 29.6 months. They excluded
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June 2, 2004:2132–41 Year in Congenital Heart Diseasehe descending thoracic aortic segment from which all major
ortopulmonary collateral arteries originate and connected
his aortic segment with the native pulmonary artery using
n interposition polytetrafluoroethylene conduit. The ven-
ricular septal defect (VSD) was closed in all patients, and
he RV was connected to the unifocalized pulmonary artery
ith a valved conduit. All patients survived and during
ollow-up (12 to 21 months); no patient required additional
nterventions. This extraordinarily different approach has
otential application in a number of patients. The downside
s that one is dealing with a long conduit from the RV
eading to deep in the chest that will have to be replaced at
later age. In addition, the segment of the descending aorta
hat is replaced with a conduit also will be small and require
urther bypass grafting later in life to prevent coarctation.
evertheless, this is a radial new approach that may prove
seful for a number of patients with this anomaly.
Murphy et al. (8) report successful early recruitment of
ongenitally disconnected pulmonary arteries. Although this
eport represents a small number of patients, it’s a reminder
hat searching for disconnected pulmonary arteries early and
aking sure they are included in eventual repair is an
mportant aspect of management.
Kanter et al. (9) report an experience in 56 patients using
freestyle porcine aortic root for valve reconstruction of the
V outflow tract in patients with conotruncal abnormalities.
arly results revealed mild or no pulmonary insufficiency in
3% and a calculated mean peak systolic gradient of only 22
m Hg.
Dearani et al. (10) report late follow-up of 1,095 patients
ndergoing ventricle to pulmonary artery conduits for the
orrection of complex cardiac anomalies. Early mortality
ecreased from 23% before 1980 to 3.7% for the most recent
ecade. Actuarial late survival for early operative survivors at
0 and 20 years was 77% and 60%, respectively. Freedom
rom reoperation for conduit failure at 10 and 20 years was
6% and 32%, respectively. These data indicate that the
omograft was superior to the porcine valve Dacron conduit
n terms of durability. Quality of life is excellent for most
atients despite the need for reoperation. The quest con-
inues for an optimal RV-PA conduit.
Boudjemline et al. (11) report an experimental study with
ercutaneous pulmonary valve replacement in a large RV
utflow tract. This group has previously performed percu-
aneous pulmonary valve replacements in patients with a RV
utflow tract 22 mm in diameter. Many postoperative
atients have larger outflow tracts with severe pulmonary
nsufficiency that could be treated by percutaneous valve
eplacement if a larger expandable stent could be developed.
herefore, they have used a nitinol stent in the shape of a
onduit with a central restriction containing an 18-mm
ovine valve. Eight of 10 devices were delivered and were
unctioning properly at two months in a chronic group of
wes. This bold new technology (Figs. 1A and 1B) has the
otential for use in a large number of patients. Hopefully, dhis methodology will be feasible for patient use in the next
hree to five years.
Niwa et al. (12) report progressive aortic root dilatation in
dults late after the repair of tetralogy of Fallot. These
uthors had data on 216 patients and identified 32 patients
ith a mean age of 36 years who had root dilation 50% of
xpected size. Patients with root dilatation had a higher
ncidence of pulmonary atresia, right arch, longer shunt to
epair interval, and more frequent conduit repair than
atients without root dilatation. Aortic valve replacement
ith root repair was required in 2 of 32 patients. These
atients require follow-up not only for pulmonary valve
nsufficiency and possible pulmonary valve replacement but
lso for aortic root dilation, which also may need treatment.
Nollert et al. (13) report risk factors for sudden death in
5 of 658 patients who had tetralogy repair at one institu-
ion at a median age of 12 years. Risk factors for sudden
eath were use of an outflow tract patch, male gender, no
revious palliation, and higher preoperative New York
eart Association status. The risk of sudden death appears
o have decreased with more recent survivors. There is still
ebate about what cardiac studies are needed in both
ymptomatic and asymptomatic patients after tetralogy
epair. Those patients with significant hemodynamic pres-
ure or volume overload and ventricular or atrial arrhythmias
igure 1. (A) The newly designed stent is shown uncovered. The extrem-
ties have a diameter of 30 mm, whereas the central part is 18 mm. (B) A
olytetrafluoroethylene membrane is covering the stent to ensure sealing of
he device. Reprinted from Boudjemline et al. (11).eserve special attention with attempted surgical or inter-
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Year in Congenital Heart Disease June 2, 2004:2132–41entional treatment of the hemodynamic problems. An
lectrophysiologic evaluation and management of their ar-
hythmia either with ablation procedures at catheterization
r at the time of surgery frequently is required.
There are an increasing number of postoperative patients
ith significant pulmonary insufficiency, RV volume over-
oad, and slow deterioration of RV function. Warner et al.
14) report on 36 patients age 15 years who underwent
ulmonary valve implantation 12 years after tetralogy repair
ith additional procedures. All patients had clinical im-
rovement in exercise capacity. There was a 30% reduction
n RV diameter. There were two patients who required
onduit replacements at one and nine years. There is still no
lear-cut indication as to when to intervene. When RV
unction is significantly impaired with an ejection fraction in
he mid-to-low 30s, improvement in the RV volume but not
n ejection fraction usually takes place. Earlier rather than
ater intervention is probably the new order of the day.
ecause most current conduits/grafts for pulmonary valve
eplacement have a half-life of only 10 years, this is a
ifficult decision to make in young patients.
d’Acoz et al. (15) report on a comparison of 44 patients
ho had a pulmonary commissurotomy for isolated pulmo-
ary stenosis with 189 patients who had transventricular
epair of tetralogy of Fallot. Patients had similar degrees of
ulmonary insufficiency. Freedom from adverse events re-
ated to RV dilation was far better, however, in patients with
solated pulmonary stenosis and commissurotomy. Pulmo-
ary insufficiency is not the only determinant of late
ymptomatic RV dilation after tetralogy repair. This com-
lication is more deleterious in tetralogy patients who have
ad right ventriculotomies, causing damage to the RV
utflow tract.
RANSPOSITION OF THE GREAT ARTERIES (TGA)
asquali et al. (16) performed a meta-analysis regarding
oronary artery pattern and outcome of arterial switch
peration. Overall, this operation has been a resounding
uccess. Debate continues about whether or not unusual
oronary artery patterns have added mortality. This analysis
howed that patients with common variants have no added
ortality but those with intramural or single coronary
rteries have significant added mortality that has persisted
ver time. Because these uncommon variants occur so
nfrequently the demonstrated added mortality is not sur-
rising.
Wetter et al. (17) reported results of arterial switch
peration for correction of 27 patients with the Taussig-
ing anomaly. Twenty-one patients had primary correction
ith one hospital death and one late death. These authors
elieve that this anomaly should be corrected in early
nfancy by VSD closure and simultaneous correction of
ssociated defects. Pulmonary artery banding may lead to
ignificant aortic insufficiency with a two-stage repair.Formigari et al. (18) report the prevalence and predictors Vf neoaortic regurgitation after arterial switch operation.
here were 61 of 173 patients who had evidence of valvular
ncompetence, which was progressive in 14 cases and led to
urgery in two cases. Multivariant analysis revealed the onset
f valvular regurgitation was correlated with the trap-door
echnique for coronary reimplantation. These authors now
ecommend the punch technique for repair for all but the
ost complicated coronary artery patterns. Although sig-
ificant aortic regurgitation is rare, it is more common with
onger follow-up. Neoaortic roots are increased in size in the
ajority of patients.
ONGENITALLY CORRECTED
RANSPOSITION OF THE GREAT ARTERIES (CCTGA)
evaney et al. (19) reported results of combined arterial
witch and Senning operation for CCTGA. Pulmonary
rtery banding was used in 15 of 23 patients either for left
entricular (LV) retraining or for congestive heart failure,
hich was unsuccessful in two because of LV dysfunction.
our patients with banding are currently awaiting repair and
ight patients had double-switch operation without band-
ng. One patient required cardiac transplantation for pro-
ressive LV failure. There were no surgically acquired
rrhythmias or residual significant hemodynamic condi-
ions. All patients are alive and well with a mean follow-up
f 36 months.
Langley et al. (20) reported 54 patients with either
CTGA or atrioventricular discordance with double-outlet
V who had anatomic repair. This comprised a Senning
rocedure plus arterial switch in 29 cases, Senning plus a
astelli procedure in 22 cases, and Senning plus intraven-
ricular rerouting in 3 cases. The PA banding was used in 9
f 29 cases or 31%. Survivals were 94% at one year and 90%
t nine years. Six have acquired LV dilatation or impaired
ystolic ventricular function. Four patients in the double
witch-group have moderate aortic regurgitation and two
equired valve replacement. Excellent functional status was
chieved in the majority of patients.
The complex operation or series of operations appears to
ork in the majority of patients although it is a formidable
hallenge. Most patients beyond childhood do poorly with
A banding for LV training. More data are needed to
etermine when to intervene. The best candidates are those
ith relatively mild dysfunction at an early age. It is difficult
end these patients to surgery when they are clinically well,
lthough the long-term outcome frequently is that of
rogressive ventricular dysfunction, atrioventricular valve
egurgitation, and congestive heart failure.
Of further importance for the patient with CCTGA is an
rticle by Bengel et al. (21), which demonstrated impaired
yocardial blood flow reserve of the anatomic RV in the
bsence of ischemic symptoms. This impairment of flow
ay be associated with reduced ventricular function of the
ystemic RV as has been suggested by other investigators.
ariations in coronary flow reserve may explain individual
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June 2, 2004:2132–41 Year in Congenital Heart Diseaseifferences in ventricular function in adults with CCTGA.
uture studies in this area could help in risk stratification for
rogressive ventricular dysfunction and thus earlier inter-
ention in selected patients.
NIVENTRICULAR HEART/FONTAN PALLIATION
aspi et al. (22) report on the effect of controlled antegrade
ulmonary blood flow and cardiac function after bidirec-
ional cavopulmonary anastomosis in 128 patients with a
ean age of six months. In group 1, there were 72 patients
ith restricted flow through a narrowed valve or by adjust-
ent of a pulmonary artery band with a goal of maintaining
he mean pulmonary artery pressure 16 mm Hg. In group
, the cavopulmonary anastomosis was the only source of
ulmonary flow. One death occurred. The mean pulmonary
rtery pressure at the end of operation was not different
etween groups. Patients in group 1 had higher oxygen
aturation and a shorter mean hospital stay than patients in
roup 2. There were no late deaths during the mean
ollow-up of 36  10 months. Oxygen saturation remained
igher and the hematocrit lower in group 1 patients with
ntegrade pulmonary flow. In addition, total pulmonary
rtery size was greater in group 1 than in group 2. Con-
rolled antegrade pulmonary flow may have a favorable effect
n cardiac function, oxygen saturation, and pulmonary
rtery growth.
Chun et al. (23) reviewed records on 166 patients who
nderwent hemi-Fontan and Fontan procedures during a
3-year period at a single institution to determine risk
actors for stroke. The overall incidence for stroke of 5.5%
or the first and final stage palliation was comparable with
arlier reports. Stroke occurred more often in the first 12
onths after surgery, but risk for stroke extended to more
han nine years after operation. Pulmonary artery banding
as related to stroke risk. Six of the nine stroke patients
ere either on aspirin or aspirin plus warfarin.
Seipelt et al. (24) report on thromboembolic complica-
ions in 101 patients who underwent a Fontan-type proce-
ure. Mean follow-up was 5.7 years. Thromboembolic
vents occurred in 15.3%. The type of operation as well as
ther known risk factors had no influence on the rate of
hromboembolism. During the first postoperative year, 7 of
he 13 events occurred. The second peak developed 10 years
ater. Patients benefited significantly from warfarin com-
ared with those who did not receive any medication. These
uthors propose that warfarin should be used in these
atients. The small numbers of patients studied and lack of
rospective data do not definitely support this proposal.
evertheless, these patients need to be observed frequently
or potential thromboembolic events and some type of
ntithrombotic therapy used. Whether warfarin will prove
o be superior to aspirin is unclear. Other anti-thrombolic
anagement strategies may prove useful as these become
vailable.
Michielson et al. (25) report on 43 patients who under- cent 44 orthotopic heart transplants for complex transpo-
ition, double-outlet RV, single ventricle, and other end-
tage structural heart disease. Hypoplastic left heart
yndrome diagnosis and failing Fontan were independent
isk factors of early mortality by regression logistic model-
ng.
Although the Fontan stage represented the only predictor
f overall mortality, the 10-year survival for all patients was
4%. Orthotopic heart transplants for structural congenital
eart disease with single ventricle physiology entails sub-
tantial early mortality and bidirectional cavopulmonary
nastomosis enables the best transition to transplant. A
ransplant should be considered in the decision-making
rocess for Fontan completion in all high-risk candidates. It
emains difficult to choose which management strategy to
ollow in high-risk patients. Patients with congenital heart
isease overall have approximately a 50% survival at 12 years
or orthotopic heart transplants. Obviously, choosing pa-
ients who are relatively more stable other than the end-
tage edematous Fontan patient will improve overall out-
ome at least in the short-term.
URGERY: OUTCOME AND FOLLOW-UP
onro et al. (26) report a retrospective analysis of 1,220
onsecutive children younger than 16 years of age who
nderwent reoperation after primary repair of a congenital
eart defect. The overall 30-day mortality was 6.9%; 171
atients had a total of 206 reoperations. Early mortality for
he first operation was 10.4% and for the second was 3.8%.
hese authors give excellent longitudinal data over 20 years
egarding reoperation for congenital cardiac defects. These
re useful data that every center should have. Although
mprovements have been made in a number of these
onditions, there is nothing like accurate historical data for
omparison of current with past success.
Almeida de Oliveira et al. (27) report on extra-anatomic
ortic bypass from ascending to descending thoracic aorta
or complex aortic coarctation or recoarctation in 18 con-
ecutive patients age 18 to 61 years (with a mean of 32
ears). Follow-up was completed in all with a mean of 5.6
ears and a range of 12 months to 22 years. No neurologic
omplications, early or late mortality, late reoperations, or
raft complications occurred. Patent grafts were confirmed
n all. There are a number of patients with complex
oarctations, recoarctations, or hypoplastic aortic arches
ho are difficult to treat with standard surgical techniques
r with catheter interventional methods. Both the ascending
orta to abdominal descending aorta graft and the ascending
o descending thoracic aortic graft reported here show
romise for relief of complex arch obstructions.
Baskett et al. (28) report on current results for surgical
trial septal defect closure in 100 consecutive patients at a
ean age of 60.5 months. There was no mortality, no
esidual atrial septal defect (ASD), and no neurological
omplications. There were three cases of postpericar-
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Year in Congenital Heart Disease June 2, 2004:2132–41iotomy syndrome and 26 pericardial effusions. The median
tay was four days. These surgical results of ASD closure in
he modern era provide an excellent gold standard to use for
oth new surgical and interventional catheterization tech-
iques for ASD closure.
ARDIAC CATHETERIZATION
ND INTERVENTIONAL TECHNIQUES
ischer et al. (29) report experience with transcatheter
losure of atrial septal defects using the Amplatzer septal
ccluder. There were 236 consecutive patients aged 6
onths to 46 years with a median of five years considered
or closure. Eighteen defects were considered too large for
losure before catheterization, and at catheterization an
dditional 18 patients did not have the device implanted
ecause the stretched diameter was too large, the device was
nstable, the device compromised the mitral valve, the
evice obstructed the right pulmonary vein, or the patient
ad additional venous anomalies or a Qp:Qs 1.5. Atrial
eptal defect closure was successful in 200 patients; 14 had
ultiple ASDs, and 8 had a septal aneurysm. Severe
omplications occurred in two cases, including air embolism
nd retroperitoneal bleeding. At follow-up at a median of
.3 years, complete closure was documented in 93% with a
esidual trivial shunt in 12 patients. There continues to be
ood results reported with this device. With careful patient
election, it can be used in most patients with secundum
trial septal defects.
Thanopoulos et al. (30) report on 10 children, aged 1.5 to
2 years, with a perimembranous ventricular septal defect
ho underwent transcatheter closure with the Amplatzer
symmetric VSD device. The VSD diameter ranged from 2
o 8 mm. After deployment, there was no residual shunt in
of 10 patients. One patient had a trivial shunt that
isappeared at three months. Three patients developed
ransient left bundle branch block; no other complications
ere observed. This device is potentially useful for closure of
erimembranous ventricular septal defects. The question as
o when to close small VSDs remains; these authors closed
everal small defects that would be left alone in most
enters. These defects are close to the aortic valve and there
re concerns with potential damage to the valve and/or the
onduction system. Further data will be needed to deter-
ine in whom this device is safe and useful.
Bacha et al. (31) report six patients with percutaneous
losure of muscular VSDs without cardiopulmonary bypass,
fter sternotomy and under transesophageal echocardio-
raphic guidance. The RV free wall was punctured, and a
ire was introduced across the defect. The Amplatzer
uscular VSD device was then inserted. No complications
rom using the technique occurred, and discharge echocar-
iography showed no significant shunt. This technique may
e useful in patients with moderately large complex mus-
ular defects which effects can be difficult to find and
ffectively close surgically. rHumpl et al. (32) report on 30 patients with pulmonary
tresia and intact ventricular septum who underwent at-
empted percutaneous valve perforation and balloon dilata-
ion of the pulmonary valve. Perforation was achieved in 27
atients. This is an effective strategy provided there is a
atent infundibulum and a lack of an RV-dependent coro-
ary circulation.
Krumsdorf et al. (33) report on the incidence and clinical
ourse of thrombus formation after patent foramen ovale
PFO) (n  593) or ASD (n  407) closure. Transesoph-
geal echocardiography was used for surveillance after four
eeks and six months. Thrombus formation in the left
trium (n  11), right atrium (n  6), or both (n  3) was
ound in 5 of the 407 ASD patients and in 15 of 593 PFO
atients. Thrombus was diagnosed in 14 of 20 patients after
our weeks and in 6 of 20 patients later on. The incidence
as 7% with the CardioSeal device (Nitinol Medical Tech-
ologies, Boston, Massachusetts), 5.7% with the STARFlex
evice (Nitinol Medical Technologies), 3.6% with the
SDOS device (Osypka Corp., Rheinfelden, Germany),
.8%, with the Helex device (W.L. Gore and Associates,
lagstaff, Arizona), and 0% with the AMPLATZER device
AGA Medical Corp., Golden Valley, Minnesota). A pre-
hrombotic disorder as a possible cause of the thrombus was
ound in two patients. Postprocedure atrial fibrillation and
ersistent septal aneurysm (n  4) were thought to be
redictors for thrombus formation. In 17 of the 20 patients,
he thrombus resolved under therapy with heparin or
arfarin, and in three patients, the thrombus was removed
urgically. There appears to be a low but definite possibility
f thrombus formation with an ASD device. Most patients
re on aspirin therapy for six months or longer after implant
nd follow-up obtained by history, clinical exam and echo-
ardiography. Surveillance of a large cohort will be needed
o clarify the risk of this complication.
Bell et al. (34) report on percutaneous endoluminal repair
f aneurysms associated with coarctation in five patients.
nce et al. (35) report percutaneous endovascular stent-graft
lacement in six consecutive patients (mean age, 49 years)
ith late aneurysm formation after coarctation repair. Place-
ent of a customized stent-graft was successful with no
0-day or 1-year intervention-related morbidity or mortal-
ty. These reports of this nonsurgical treatment of aortic
neurysm post coarctation repair are encouraging.
Duke et al. (36) report efficacy and safety of stent
edilation in 60 patients with either coarctation or pulmo-
ary artery branch stenosis. Neointimal thickening 1 mm
as detected in 6 of 12 coarctation stents and 9 of 21
tented pulmonary arteries. These authors conclude that
eointimal proliferation can be precipitated by overdilating
tents at implantation. Redilation using balloons matched to
he distal vessel diameter increased lumen size but may not
ptimize diameter. Redilation is effective whether the indi-
ation for redilation is resistant stenosis at implantation,
nderexpansion at implant, neointimal proliferation, or
elative stenosis caused by growth. There was one patient
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June 2, 2004:2132–41 Year in Congenital Heart Diseaseith massive hemorrhage from pulmonary artery rupture
istal to stent redilation. This report is encouraging that
edilation therapy can be performed with good efficacy.
Gewillig et al. (37) report on stenting the neonatal arterial
uct in duct-dependent pulmonary circulation. All stents
ere deployed with adequate pulmonary flow at early- and
idterm follow-up. There were no procedure-related com-
lications. One patient died from sepsis. All patients had
elief of cyanosis for three to four months. Here is another
ethodology to provide adequate pulmonary artery blood
ow in patients with relatively short, straight ducts.
Michel-Behnke et al. (38) report on stenting the ductus
rteriosus and banding the pulmonary arteries in 20 patients
ith hypoplastic left heart syndrome. Stenting of the arterial
uctal combined with bilateral pulmonary artery banding
epresents another approach to these patients. The ability to
chieve good early palliation and then perform both the
orwood I and II operations in one stage at 3.5 to 6 months
as definite theoretical advantages. Whether this will prove
easible in the majority of patients with low morbidity or
ortality remains to be seen.
EUROLOGICAL COMPLICATIONS
FTER CARDIAC SURGERY
ellinger et al. (39) report on developmental neurological
nd speech outcomes at eight years of age in 155 of 160
ligible children who had arterial switch for TGA. Patients
ere assigned either total circulatory arrest or low-flow
ypass. Treatments groups did not differ in neurologic
tatus, full-scale or performance IQ score, academic
chievement, memory, problem solving, and visual-motor
ntegration. Children assigned to circulatory arrest per-
ormed worse on tests of motor function. Assignment to
ow-flow bypass was associated with a more impulsive
esponse style on a continuous performance test of vigilance
nd worse behavior as rated by teachers. These studies
ndicate an overall favorable outcome in the majority of
nfants undergoing this complex surgery. Although circula-
ory arrest has been associated with greater functional
eficits than low-flow cardiopulmonary bypass, both strat-
gies have an increased risk of neurodevelopmental vulner-
bilities.
Gaynor et al. (40) evaluated 244 patients who were 6
onths of age undergoing cardiopulmonary bypass for
epair of congenital heart defects and evaluated an associa-
ion between apolipoprotein E genotype and postoperative
eurodevelopmental dysfunction. The apolipoprotein E2
llele was associated with a worse neurologic outcome as
ssessed by the Psychomotor Developmental Index. This
nteresting study indicates one reason for the differences in
utcomes of patients who have similar postoperative
ourses. The particular allele associated with worse outcome
aries with ethnicity; in this study it accounted for only
3.5% of the cohort. tEDICAL THERAPY
eltes et al. (41) report on a randomized double-blind
lacebo controlled trial, including 1,287 children with
ongenital heart disease (CHD) randomly assigned to
eceive five monthly intramuscular injections of palivizumab
r placebo for protection from respiratory syncytial virus
RSV) complications. Palivizumab recipients had a 45%
elative reduction in RSV hospitalizations, a 56% reduction
n total days of hospitalization, and a 73% reduction in total
SV hospital days with increased supplemental oxygen.
dverse events were similar in the treatment groups. This
andomized trial shows the benefit in terms of RSV hospi-
alizations in using intramuscular hyperimmune RSV glob-
lin to ameliorate RSV infections in infants with CHD.
lthough the use of hyperimmune globulin did not prevent
SV infections, it did lessen the severity of this infection.
his treatment is expensive but it is effective and its use has
een adopted in a policy statement by the American
cademy of Pediatrics Committee on Infectious Diseases.
Hoffman et al. (42) reported on a double-blind placebo
ontrolled trial with three parallel groups regarding the
fficacy and safety of milrinone in preventing low cardiac
utput in infants and children after corrective surgery for
ongenital heart disease. Among 238 patients, the admin-
stration of high-dose milrinone significantly reduced the
isk of low cardiac output syndrome compared with a
lacebo with a relatively risk reduction of 55%. There were
wo deaths both after infusion of study drug. Both this study
nd the previous palivizumab study indicate the feasibility of
onducting relatively large-scale placebo controlled trials in
hildren with good evidence-based data for subsequent
linical use.
Schulze-Neick et al. (43) intravenous sildenafil in 12
hildren with CHD and increased pulmonary vascular
esistance. Intravenous sildenafil more effectively reduced
ulmonary vascular resistance than nitric oxide both in the
cath laboratory” patient group and in the postoperative
atients group. Although the vasodilating effects of silden-
fil showed pulmonary selectivity, it was associated with
ntrapulmonary shunting in the postoperative patient. There
s an increasing but small armamentarium of medications
or use in patients with pulmonary vascular resistance
levation. Both intravenous and oral sildenafil may be
fficacious in certain patients with elevated pulmonary
ascular resistance.
Ringel and Peddy (44) report the use of spironolactone in
atients with protein-losing enteropathy who have had
ontan palliation. These authors studied three patients with
rotein-losing enteropathy that was resistant to all therapy.
pironolactone in doses from 2.3 to 5 mg/kg/day induced
emission for two to three years. Although this report
epresents a small number of patients, this rare complication
s such a serious problem that any new possibilities for
reatment are welcome.
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lexander et al. (45) report the use of implantable cardio-
erter defibrillator (ICD) therapy in 76 patients 30 years
ith CHD, primary electrical disease, hypertrophic cardio-
yopathy, or idiopathic dilated cardiomyopathy. Trans-
enous dual-chamber ICDs were implanted in 29 patients.
ver a median two-year follow-up, 28% of patients received
ppropriate shocks, and 25% experienced inappropriate
hocks. With multivariate analysis, growth strongly corre-
ated with lead failure. Complications occurred in 29 pa-
ients, including lead failure in 29%, ICD “storm” with
equential shocks in 5 patients and infection in 2 patients.
o deaths were attributable to ICD placement or device
ailure. Implantable cardioverter defibrillator therapy can
ffectively manage malignant arrhythmias in selected pa-
ients. Spurious shocks or ICD storm may increase morbid-
ty and emphasize the need for concomitant medical and
blative therapy. The application of ICD therapy to selected
ediatric patients remains an evolving strategy. It can be life
aving but it is not without its complications.
Zimmerman et al. (46) report acute hemodynamic benefit
f multisite ventricular pacing after surgery in 29 patients
ge 1 week to 17 years with prolonged QRS interval who
ad atrial and ventricular unipolar epicardial temporary
acing leads placed at surgery. Systolic blood pressure
mproved in all by a mean of 9.7% and cardiac index
mproved in 19 of 21 patients with no change in 2 patients.
acing facilitated weaning from bypass in two patients.
ultisite ventricular pacing may be another addition to
herapy for the failing heart with a congenital defect. This
ay be applicable both to biventricular circulation patients
nd those with a single ventricle.
Strasburger et al. (47) report the use of amiodarone
herapy for drug-refractory fetal tachycardia. These fetuses
ere treated transplacentally with a maternal loading dose
f oral amiodarone for two to seven days, followed by daily
aintenance therapy for 1 to 15 weeks. Digoxin therapy
as continued. Amiodarone or amiodarone combination
herapy converted 14 of 15 with SVT. Amiodarone-related
dverse effects were transient in five infants and eight
others. Mean gestational age at delivery was 37 weeks
ith 100% survival. Orally administered maternal amioda-
one therapy can be a safe and effective treatment for
rug-refractory fetal tachycardia even when accompanied by
ydrops fetalis or ventricular dysfunction.
Gaita et al. (48) report six patients from two families who
ubmitted to extensive work-up because of syncope, palpi-
ations, and resuscitated cardiac arrest in the presence of a
ositive family history for sudden death. Electrocardiograms
xhibited a QT interval 280 ms (QTc 300 ms). During
lectrophysiological study, short atrial and ventricular re-
ractory periods were documented in all and increased
entricular vulnerability to fibrillation in three of four
atients. This short QT syndrome is characterized by
amilial sudden death, short refractory periods, and induc- pble ventricular fibrillation. It is important to recognize this
lectrocardiographic pattern because it is related to a high
isk of sudden death in young, otherwise healthy subjects.
ENETIC CAUSES OF CHD
uncke et al. (49) report missense mutations and gene
nterruption in Prosit240, a novel Trap240-like gene, in
igure 2. (A) Axial computed tomography angiography image at the level
f the main pulmonary arteries demonstrates severe dilation, with the main
ulmonary artery measuring 71 mm. There is an associated eccentric
rregular thrombus in the left main artery (short arrows). A tiny focus of
alcification is noted in the posterior wall of the right pulmonary artery
long arrow). (B) Axial image at the level of lung bases showing extension
f the thrombus into the segmental basal arteries of the left lower lobe
short arrows). Reprinted from Silversides et al. (51).atients with TGA. Garg et al. (50) report GATA4
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evealed an interaction with TBX5. These two articles
epresent part of a rapidly developing body of knowledge
egarding genetic causes of congenital heart disease, here-
ofore unexpected. The knowledge base in this area keeps
xpanding and it remains difficult to keep current.
DULT CHD
ilversides et al. (51) report on findings in 34 patients age 42
10 years with Eisenmenger’s syndrome who underwent
omputed tomograph angiograms to determine the inci-
ence of pulmonary thrombosis. The prevalence of proximal
ulmonary artery thrombus was 21% and more distal
hrombus was observed in 43% of the patients who had
hrombus in proximal pulmonary arteries (Fig. 2). The
atients with thrombus were more likely to be female and to
ave lower oxygen saturations. Difference in functional
tatus did not identify patients at high risk. Unfortunately,
arfarin anticoagulation can lead to severe bleeding in these
atients who are prone to develop hemoptysis. Thus, this
trategy is fraught with difficulty, and the risk-benefit of
rophylactic warfarin therapy remains unclear.
Connolly et al. (52) report cranial magnetic resonance
ngiographic study in 100 patients with coarctation of the
orta to detect intracranial aneurysms. The frequency was
ignificantly higher than that predicted in the general
opulation (10% vs. 2%). No clinical or geographical dif-
erences were found between patients with coarctation and
neurysms and patients with coarctations and no aneurysms.
hese authors suggest that noninvasive cerebral imaging to
creen for aneurysms should be considered in patients with
oarctation.
Silversides et al. (53) report on the early and intermediate
erm outcomes of pregnancy with congenital aortic stenosis
n 49 pregnancies in 39 women. Only patients with severe
ortic stenosis with a peak gradient 64 mm Hg or aortic
alve area  1 cm2 experienced maternal complications,
ncluding 2 of 29 with pulmonary edema and 1 of 29 with
trial arrhythmias. There were no maternal deaths, and
here were no fetal or neonatal deaths. There were five
remature births. This series is encouraging in regard to the
bility of women with moderate aortic stenosis and in most
ases, even with severe stenosis to tolerate pregnancy. There
as a high incidence of surgical intervention after pregnancy
n women with severe aortic stenosis, and one should
onsider of aortic valve intervention before pregnancy in
hese patients.
Vogel et al. (54) report on systemic ventricular function in
atients with transposition of the great arteries after atrial
epair. These authors examined 55 controls and 80 patients
ith a mean age of 22 years who had undergone atrial repair
t the age of 8 months with a range of 0.3 to 72 months.
ight ventricular systolic function was derived by analysis of
ressure-volume relationships at rest and during dobut-
mine stress. In the group as a whole, isovolumic myocardialcceleration was reduced compared with the subpulmonary
V and the systemic LV of controls. There was abnormal
all motion in 44 patients, which was associated with
educed isovolumic myocardial acceleration. Diastolic veloc-
ties were also abnormal but unrelated to the presence of
all motion abnormalities.
Studies of the systemic RV continue to show abnormal-
ties both in the laboratory and clinically as a function of
ge. We will need all of the therapeutic armamentarium for
reatment of congestive failure for the increasing number of
atients with systemic RVs who have had successful surgical
ntervention in the past.
Prasad et al. (55) assessed the role of contrast enhanced
hree-dimensional magnetic resonance angiography (MRA)
s a minimally invasive technique to allow detailed studies in
single breath-hold for adult patients with major aortopul-
onary collateral arteries and partial anomalous pulmonary
enous drainage. This modality was used in 29 consecutive
atients with a diagnosis of multiple collateral pulmonary
rteries (n  16) and partial anomalous pulmonary venous
rainage (n  13). There was excellent correlation between
he MRA and cardiac catheterization, echocardiography,
nd surgical inspection. Additional information was gained
or patients with major aortopulmonary collateral arteries on
onfluence and size of pulmonary arteries, pulmonary artery
tenosis aneurysmal dilatation of the pulmonary artery and
dditional vascular abnormalities. Shunt assessment, in
ases without shunt (9 of 16 patients), showed patency in all
ases. For adults with partial anomalous pulmonary venous
rainage, further information was obtained on drainage
rigin in 11 of 13. There were no complications. Both
RA and rapid computed tomograph can provide out-
tanding images for complex conditions such as these.
hese can be extremely helpful prior to surgery or planned
atheter intervention.
eprint requests and correspondence: Dr. Thomas P. Graham,
r., D2220 Medical Center North, Vanderbilt University Medical
enter, Nashville, Tennessee 37232. E-mail: tom.graham@
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